Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis Vincent Billioud, Alexander C. Ford,

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference Airi Jussila, Lauri J. Virta, Veikko Salomaa,

Work disability in inflammatory bowel disease

The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and.

The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe Peter.

Risk of colorectal cancer and small bowel adenocarcinoma in Crohn's disease: A population-based study from western Hungary 1977–2008 Peter Laszlo Lakatos,

IBD in the elderly population: Results from a population-based study in Western Hungary, 1977��2008 Peter Laszlo Lakatos, Gyula David, Tunde Pandur,

How do psychological variables influence coping strategies in inflammatory bowel disease? Marta Iglesias-Rey, Manuel Barreiro-de Acosta, Francisco Caamaño-Isorna,

Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum? Tamás Molnár, Klaudia Farkas, Ferenc.

Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro.

Antonio Cascio, Chiara Iaria, Paolo Ruggeri, Walter Fries

Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody?

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

YouTube® and inflammatory bowel disease

Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out? Christian Jakobsen, Vibeke Wewer, Frederikke Urne,

Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature Gurhan.

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference Airi Jussila, Lauri J. Virta, Veikko Salomaa,

Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD) Mariam Aguas, Vicente Garrigues,

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

Anterior ischemic optic neuropathy in a patient with Crohn's disease and aberrant MTHFR and GPIIIa gene variants T. Felekis, K.H. Katsanos, C.D. Zois,

Serum prohepcidin levels in chronic inflammatory bowel diseases

Charlotte de Bie, Angelika Kindermann, Johanna Escher

N. Kjaersgaard Nielsen, V. Wewer, L. Skafte, A. Paerregaard

Endothelial function and cardiovascular risk in active inflammatory bowel diseases Mariabeatrice Principi, Mario Mastrolonardo, Pietro Scicchitano, Michele.

Filiform polyposis associated with sigmoid diverticulitis in a patient without inflammatory bowel disease Hyun-Soo Kim, Kil Yeon Lee, Youn Wha Kim Journal.

Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population- based cohort followed for ten years May-Bente Bengtson, Camilla.

Public awareness of Crohn's disease and ulcerative colitis: A national survey Sieglinde Angelberger, Harald Vogelsang, Gottfried Novacek, Wolfgang Miehsler,

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

B. Sicilia, F. Arribas, J. Nerín, C. López Miguel, R. Vicente, F

Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out? Christian Jakobsen, Vibeke Wewer, Frederikke Urne,

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases Danuta Owczarek,

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Gord Blackhouse, Nazila Assasi,

Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature Dana Duricova, Johan Burisch,

Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis Thomas W. Lee, Michael.

Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case–Control and Cohort Studies Guillaume Pineton de Chambrun, Luc.

Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease Laurent Peyrin-Biroulet, Gert.

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Prevalence of Irritable Bowel Syndrome–type Symptoms in Patients With Celiac Disease: A Meta-analysis Anita Sainsbury, David S. Sanders, Alexander C.

Clinical trials in luminal Crohn's disease: A historical perspective

Xian-rui Wu, Saurabh Mukewar, Ravi P. Kiran, Feza H

The usefulness of factor XIII levels in Crohn's disease

Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients Marko Brinar, Séverine.

Laurent Peyrin-Biroulet, Julián Panés, William J

Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux–Type Symptoms in the Community: A Systematic Review and Meta-analysis Leonardo H.

Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis Niels Teich, Tobias Klugmann Journal of.

Seth Lipka, Seymour Katz, Lev Ginzburg Journal of Crohn's and Colitis

Osteoporosis in inflammatory bowel disease

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis M. De Vos, O. Dewit, G. D'Haens,

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

Pathogenic Escherichia coli in inflammatory bowel diseases

Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation Sjoerd F. Bakker,

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Gord Blackhouse, Nazila Assasi,

Volume 151, Issue 1, Pages e4 (July 2016)

H.L. Nielsen, J. Engberg, T. Ejlertsen, R. Bücker, H. Nielsen

Subrata Ghosh, Benjamin Pariente, Diane R

Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA- based protocol in UK subjects with inflammatory bowel disease suitable.

Does active smoking really influence the course of Crohn's disease

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled.

Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis S.D. McLaughlin, A. Culkin,

Bowel sonography in occlusive Crohn's disease

Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors Anilga Moradkhani, Linda.

What Is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Systematic Review and Meta-analysis Alexander C. Ford,

Volume 151, Issue 1, Pages e4 (July 2016)

Rebecca M. Lovell, Alexander C. Ford

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis Shailja C.

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases Xavier Roblin, Hubert Marotte, Melanie.

Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Siddharth.

Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic.

Systematic Review and Meta-analysis of the Prevalence of Irritable Bowel Syndrome in Individuals With Dyspepsia Alexander C. Ford, Avantika Marwaha,

Thiopurines and Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease: A Meta-analysis Tine Jess, Anthony Lopez, Mikael Andersson,

Presentation transcript:

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis Vincent Billioud, Alexander C. Ford, Emilie Del Tedesco, Jean-Frédéric Colombel, Xavier Roblin, Laurent Peyrin-Biroulet Journal of Crohn's and Colitis Volume 7, Issue 11, Pages 853-867 (December 2013) DOI: 10.1016/j.crohns.2013.01.014 Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions

Figure 1 Flow diagram of assessment of studies identified in the systematic review. Journal of Crohn's and Colitis 2013 7, 853-867DOI: (10.1016/j.crohns.2013.01.014) Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions

Figure 2 Pooled odds ratio for overall postoperative complications (A) and infectious complications (B) in anti-TNF and non-anti-TNF treated CD patients. Journal of Crohn's and Colitis 2013 7, 853-867DOI: (10.1016/j.crohns.2013.01.014) Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions

Figure 3 Pooled odds ratio for overall postoperative complications (A) and infectious complications (B) in anti-TNF and non-anti-TNF treated UC/IBD-U patients. Journal of Crohn's and Colitis 2013 7, 853-867DOI: (10.1016/j.crohns.2013.01.014) Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions

Figure 4 Pooled odds ratio for overall postoperative complications (A) and infectious complications (B) in anti-TNF and non-anti-TNF treated IBD patients. Journal of Crohn's and Colitis 2013 7, 853-867DOI: (10.1016/j.crohns.2013.01.014) Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions

Supplementary Fig. 1 Pooled odds ratio for non-infectious postoperative complications in anti-TNF and non-anti-TNF treated UC/IBD-U patients. Journal of Crohn's and Colitis 2013 7, 853-867DOI: (10.1016/j.crohns.2013.01.014) Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions

Supplementary Fig. 2 Pooled odds ratio for non-infectious postoperative complications in anti-TNF and non-anti-TNF treated IBD patients. Journal of Crohn's and Colitis 2013 7, 853-867DOI: (10.1016/j.crohns.2013.01.014) Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions

Supplementary Fig. 3 Pooled odds ratio for overall postoperative complications in anti-TNF and non-anti-TNF treated CD patients (A) and UC/IBD-U patients (B). Journal of Crohn's and Colitis 2013 7, 853-867DOI: (10.1016/j.crohns.2013.01.014) Copyright © 2013 European Crohn's and Colitis Organisation Terms and Conditions